Rapid HBV DNA decrease (week 12) is an important prognostic factor for first-line treatment with adefovir dipivoxil for chronic hepatitis B

Journal of Gastroenterology

Volumn 44, Issue 8, 2009, Pages 871-877

  Hass, Holger G ^a   Bock, Thomas ^b   Nehls, Oliver ^c   Kaiser, Stephan ^d  

^a Paracelsus Hospital   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c Dept Int Med Gastroenterol/H   (Germany)

^d Center for Liver and Infectious Diseases   (Germany)

Author keywords

Adefovirdipivoxil; Chronic hepatitis B; HBV genotype; Viral kinetics

Indexed keywords

ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; CREATINE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; VIRUS DNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOSE RESPONSE; DRUG WITHDRAWAL; FEMALE; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; SKIN ALLERGY; VIRUS LOAD; VIRUS RESISTANCE;

ADENINE; ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; PROGNOSIS; RETROSPECTIVE STUDIES; VIRAL LOAD;

EID: 69349092791     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-009-0078-y     Document Type: Article

References (29)

1. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2001;34:1225-41.
2. Maddrey WC. Hepatitis B: An important public health issue. J Med Virol. 2000;61:362-6.
3. Chang CN, Skalski V, Hua Zhou J, Cheng YC. Biochemical pharmacology of (+)-and (-)-2′,3′-dideoxy-3′-thiacytidine as anti-hepatitis B virus agents. J Biol Chem. 1992;267:22414-20.
4. Tassopoulos NC, Volpes R, Pastore G, Heathcote J, Buti M, Goldin RD, et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA positive (precore mutant) chronic hepatitis B. Hepatology. 1999;29:889-96.
5. Leung N. Treatment of chronic hepatitis B: Case selection and duration of therapy. J Gastroenterol Hepatol. 2002;17:409-14.
6. Lau DT, Khokhar F, Doo E, Ghany MG, Herion D, Park Y, et al. Long-term therapy of chronic hepatitis B with lamivudine. Hepatology. 2000;32:828-34.
7. Liaw YF, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology. 2000;119:172-80.
8. Lada O, Benhamou Y, Cahour A, Katlama C, Poynard T, Thibault V. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir. Antivir Ther. 2004;9:353-63.
9. Van Bömmel F, Wünsche T, Mauss S, Reinke P, Bergk A, Schürmann D, et al. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology. 2004;40:1421-5.
10. Lim SG, Ng TM, Kung N, Krastev Z, Volfova M, Husa P, et al. A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B. Arch Intern Med. 2006;166:49-56.
11. Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med. 2003;348:808-16.
12. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med. 2003;348:800-7.
13. Wong SN, Lok AS. Update on viral hepatitis: 2005. Curr Opin Gastroenterol. 2006;22:241-7.
14. Lampertico P, Viganò M, Manenti E, Iavarone M, Sablon E, Colombo M. Low resistance to adefovir combined with lamivudine: A 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology. 2007;133:1445-51.
15. Pawlotsky JM, Dusheiko G, Hatzakis A, Lau D, Lau G, Liang TJ, et al. Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: Recommendations for a standardized approach. Gastroenterology. 2008;134:405-15.
16. Song le H, Binh VQ, Duy DN, Kun JF, Bock TC, Kremsner PG, et al. Serum cytokine profiles associated with clinical presentation in Vietnamese infected with hepatitis B virus. J Clin Virol. 2003;28:93-103.
17. Song le H, Binh VQ, Duy DN, Jüliger S, Bock TC, Luty AJ, et al. Mannose-binding lectin gene polymorphisms and hepatitis B virus infection in Vietnamese patients. Mut Res. 2003;522:119-25.
18. Peters MG, Hann Hw H, Martin P, Heathcote EJ, Buggisch P, Rubin R, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology. 2004;126:91-101.
19. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology. 2006;131:1743-51.
20. Westland C, Delaney W 4th, Yang H, Chen SS, Marcellin P, Hadziyannis S, et al. Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil. Gastroenterology. 2003;125:107-16.
21. Yuen MF, Sablon E, Libbrecht E, Van De Velde H, Wong DK, Fung J, et al. Significance of viral load, core promoter/precore mutations and specific sequences of polymerase gene in HBV-infected patients on 3-year lamivudine treatment. Antivir Ther. 2006;11:779-86.
22. Chan HL, Wong VW, Tse CH, Chim AM, Chan HY, Wong GL, et al. Early virological suppression is associated with good maintained response to adefovir dipivoxil in lamivudine resistant chronic hepatitis B. Aliment Pharmacol Ther. 2007;25:891-8.
23. Werle B, Cinquin K, Marcellin P, Pol S, Maynard M, Trépo C, et al. Evolution of hepatitis B viral load and viral genome sequence during adefovir dipivoxil therapy. J Viral Hepat. 2004;11:74-83.
24. Hass HG, Bock T, Nehls O, Kaiser S. Early viral kinetics is a strong prognostic predictor for long-term response and occurence of YMDD mutations in patients treated with lamivudine for chronic Hepatitis B. Liver. (submitted).
25. Lau GK, Cooksley H, Ribeiro RM, Powers KA, Shudo E, Bowden S, et al. Impact of early viral kinetics on T-cell reactivity during antiviral therapy in chronic hepatitis B. Antivir Ther. 2007;12:705-18.
26. Tillmann HL. Antiviral therapy and resistance with hepatitis B virus infection. World J Gastroenterol. 2007;13:125-40.
27. Chen CH, Wang JH, Lee CM, Hung CH, Hu TH, Wang JC, et al. Virological response and incidence of adefovir resistance in lamivudine-resistant patients treated with adefovir dipivoxil. Antivir Ther. 2006;11:771-8.
28. Yeon JE, Yoo W, Hong SP, Chang YJ, Yu SK, Kim JH, et al. Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil. Gut. 2006;55:1488-95.
29. Lee YS, Suh DJ, Lim YS, Jung SW, Kim KM, Lee HC, et al. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology. 2006;43:1385-91.